详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Intraoperative electron beam radiotherapy combined with gemcitabine and PD-L1 inhibitors for unresectable pancreatic cancer: Report of 3 cases

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Liver Transplantation Center and HBP Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

出处：

DOI：

ISSN：

关键词： Pancreatic cancer Intraoperative radiotherapy PD-L1 inhibitor Gemcitabine

摘要：

Dear Editor, Pancreatic cancer is a leading cause of cancer-related death worldwide, with a 5-year survival rate of approximately 4 % following diagnosis.1 Due to the lack of typical clinical symptoms in the early stages, 80e85 % of patients are diagnosed with advanced, unresectable disease.2 Current treatment strategies for unresectable pancreatic cancer include radiotherapy, chemotherapy, and immunotherapy.3 Nowadays, intraoperative radiotherapy (IORT) has shown promising results in improving the prognosis of patients with unresectable pancreatic cancer by delivering a single high dose of ionizing radiation to the pancreatic bed.3 However, to date, no cases have been reported that combine IORT, chemotherapy, and immunotherapy for the treatment of unresectable, locally advanced pancreatic cancer.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区外科

第一作者：

第一作者机构： [1]Liver Transplantation Center and HBP Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study [2]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [3]Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China [4]Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer [5]Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential [6]IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells [7]吉西他滨联合奥沙利铂治疗晚期胰腺癌患者的疗效 [8]S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. [9]Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study [10]NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-kappa B activation